Compare COSM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | APRE |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.5M |
| IPO Year | 2009 | 2019 |
| Metric | COSM | APRE |
|---|---|---|
| Price | $0.22 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | ★ 2.7M | 381.5K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $54.08 | N/A |
| Revenue Next Year | $32.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.16 | $0.55 |
| 52 Week High | $1.32 | $1.69 |
| Indicator | COSM | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | N/A |
| Support Level | $0.17 | N/A |
| Resistance Level | $0.28 | N/A |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 44.37 | 0.00 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.